Not Signed In - Takeda Submits New Drug Application For Extended-release Type 2 Diabetes Medication, ACTOplus MetTM
Thu, 06 Apr 2006 03:00 PM EST
... Takeda Global Research & Development Center (TGR&D) today announced that the company has submitted a New Drug Application (NDA) for an extended-release version of the combination medication ACTOplus met TM (pioglitazone HCl and metformin HCl) to the United States Food and Drug Administration (FDA) for the treatment of type 2 diabetes... click link for more info. ...
Related Topics
- Diabetes - Type 2
- Diabetes - Type 1
- Juvenile Diabetes
- Niacin Extended Release
- Carbinoxamine and Pseudoephedrine Extended-Release Tablets
- Diabetes and Pregnancy
- Niacin extended-release and lovastatin
- Lovastatin Extended Release
- Medications
- Medication
- Valproic Acid Delayed or Extended-Release or Sprinkle Capsule
- Aspirin and Extended-Release Dipyridamole
- Diabetes Insipidus
- Metformin Extended-Release
- Pseudoephedrine Extended Release
- Rosiglitazone
- Gestational Diabetes
- Bupropion Extended-Release
- Chlorpromazine Extended-Release Capsules
- Methylphenidate ER
email this page
print this page
bookmark this page
feedback on this page
